StockData
Protagonist Therapeutics, Inc logo

Protagonist Therapeutics, Inc (PTGX) stock

PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)

Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –

Protagonist Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Protagonist Therapeutics's enterprise value was $7.94B on Nov 11, 2026, against $5.04B a year earlier. Over the last 5 years it ranged from $78.76M to $8.77B, with a median of $1.71B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$7.94B+62.8%
2025Dec 31, 2025$4.88B+166.7%
2024Dec 31, 2024$1.83B+82.7%
2023Dec 29, 2023$1.00B+271.7%
2022Dec 30, 2022$269.32M-79.5%
2021Dec 31, 2021$1.32B+135.7%
2020Dec 31, 2020$558.29M+931.7%
2019Dec 31, 2019$54.11M-27.9%
2018Dec 31, 2018$75.02M-75.2%
2017Dec 29, 2017$302.04M+11.2%
2016Dec 30, 2016$271.53M–

More Protagonist Therapeutics figures

See a number that looks wrong?